Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Trinity Biotech (TRIBY) -- Ignore unavailable to you. Want to Upgrade?

To: dowman who wrote (9884)	7/25/1998 2:02:00 PM
From: PAR	Respond to of 14328

Hey SABOTUER, are you sure we shouldn't be calling you 'ringer'? Thanks for your input along the way.

To: dowman who wrote (9884)	7/25/1998 4:01:00 PM
From: Ron Luhmann	Read Replies (1) \| Respond to of 14328

hey, you forgot liar & poster of totally false information...refusing to admit it, not to mention always asking someone else to make the call/do the work or provide reference sources....since yours are so secret(not to mention WRONG)... don't break your arm attempting to pat yourself on the back with issues that have been obvious for some time....someone liked what they heard TRIBY was being bought not sold on Thurs/Fri...

To: dowman who wrote (9884)	7/25/1998 9:30:00 PM
From: Stephen Smith	Read Replies (1) \| Respond to of 14328

Dowman - Unigold HIV approval is in FDA's hands now, not Trinity's. TRIBY has quite honest about saying that they don't know when or if this test will receive FDA approval. The test is obviously a good one or SKB would not be putting their name on it and selling it in Africa. SKB is a major drug company with a reputation to uphold. The company did give some figures out about sales. They gave the monthly revenue figure for the Malaysia HIV test, which they said was about 80K. When asked about SKB HIV sales, they said they were somewhat less than half of the Malaysia numbers. They gave me an estimate months ago of 1 million revenue this year for the Malaysia contract and their CC info about this is right in line with what they told me back then. Do you really expect them to break down the numbers on all their products and put it out in a press release? I consult for Glaxo Wellcome and I certainly don't see them doing that. I also think that management could have been more forthcoming about the options, and I agree that dilution has been a problem. I just don't get where you are coming from about the products and revenues. It is obvious that some of their products bring in very little revenue. That does not translate into saying they are not worth having. Customers appreciate being able to get everything or almost everything from one vendor. It helps Trinity to sell the products that do sell better. I'm looking for an answer from you about the points I'm making. It seems to me that you just want to be negative. I don't know what your motive is.